Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Cinta Pallarés et al.|The Lancet Oncology|2012Cited by 5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerRafael Rosell, Miquel Tarón, Teresa Morán et al.|New England Journal of Medicine|2009Cited by 2.4k
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and MelanomaAleix Prat, Enriqueta Felip, Alejandro Navarro et al.|Cancer Research|2017Cited by 480
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)Miguel García-Pardo, Laura Mezquita, Marta García de Herreros et al.|Therapeutic Advances in Medical Oncology|2025Cited by 2